AXLRx · Payer and HTA Brief

What US payers will require from your NSCLC asset.

The coverage criteria, prior-authorisation architecture, and evidence standard payers apply to NSCLC IO agents — mapped against your trial design, before access strategy is locked.

NSCLC · US MarketPayer and HTA72-Hour Delivery30 Pages · 3 Outputs100% Live-Sourced

Commission This Brief View a sample exhibit ↓

The Access Reality

Payers evaluate your asset against the coverage precedents already written for incumbents — not against your trial design. That conversation starts 12–18 months pre-approval.

US payer coverage criteria for NSCLC IO agents were written around the early KEYNOTE and CheckMate trials. New entrants are judged against those precedents. The evidence a payer will demand at your approval is already visible in the coverage policies for existing agents.

Prior-authorisation architecture — biomarker requirements, step edits, line restrictions — determines real-world access as much as the label does. A broad label with restrictive PA is a narrow market.

Below, we map the coverage architecture and the evidence standard, and run a gap analysis against your clinical package.

12–18mo

pre-approval window to shape the payer conversation

coverage postures — broad, restricted, step-gated — to map per agent

prior-auth architecture often matters more than the label

100%

of coverage claims cited to a live policy document

What Your Team Needs Answered

Five questions. Each section is built to answer one of them.

Structured by decision, not by topic — every section feeds a specific access call.

What coverage criteria do payers apply to NSCLC IO agents today?

DeliversCoverage posture by agent · biomarker and line restrictions · policy citations

What does the prior-auth architecture actually require?

DeliversPA criteria · step edits · documentation burden by payer archetype

What evidence standard will payers apply to your approval?

DeliversEvidence threshold from incumbent precedents · endpoint expectations

Where does your clinical package clear the bar — and where not?

DeliversGap analysis vs. your trial design · risk areas · mitigations

What HTA and economic evidence will be expected?

DeliversEconomic evidence expectations · comparator framing · value-story inputs

Scoped to your trial design and proposed label — not the category average.

Scope Your Work

Inside the Brief

Eight sections. Every section structured around a named commercial question.

What your team receives. Section scope is built around your asset and proposed label — not pulled from a generic template.

AXLRx™ · Intelligence Brief · Payer and HTA

Non-Small Cell Lung Cancer — Payer and HTA, US

Prepared for [Client] · Q2 2026 · 30 pages · Confidential

Contents

01The Access Framepp. 1–3
- Why coverage precedent, not your trial, sets the bar
- The access decisions to make pre-approval
- What secondary policy review resolves vs. primary payer research
02Coverage Architecturepp. 4–9
- Coverage posture by agent — broad, restricted, step-gated
- Biomarker and line restrictions in policy
- Regional and PBM variation
03Prior-Auth Realitypp. 10–14
- PA criteria and documentation burden
- Step edits and their commercial impact
- Where PA narrows a broad label
04The Evidence Standardpp. 15–19
- The threshold from incumbent precedents
- Endpoint and comparator expectations
- What payers discount or reject
05Gap Analysispp. 20–24
- Where your clinical package clears the bar
- Risk areas and likely pushback
- Evidence-generation options to close gaps
06HTA & Economicspp. 25–27
- Economic evidence expectations
- Comparator framing and value story
- Budget-impact considerations
07The Assumption Registerpp. 28–29
- Which policy positions are current vs. evolving
- Inputs that drive access-timing variance
- Sensitivity on coverage-decision timing
08Client Alignment Questionspp. 30
- Payer conversations to start 12–18 months out
- Evidence gaps requiring primary payer research
- Decisions contingent on label and trial outcomes
— Source Annex — all PMIDs, ClinicalTrials.gov IDs, and live URLs pp. A1–A6

At a glance

30pages across 8 structured sections

5commercial questions answered

72hfrom scope confirmation to delivery

100%of figures cited to live source

Readout call included

All deliveries include a 30-minute call with your analyst — to walk through findings and identify what your team needs to resolve next.

What You Receive

Three outputs delivered within 72 hours. Each built for a different role in your commercial team.

The intelligence analysis, the working model, and the board summary — delivered together.

Core Deliverable

PDF

PDF · ~30 pages

Intelligence Brief

Structured for sequential reading by your launch lead, medical affairs director, and market access team. Every exhibit sourced.

Executive summary — 3 pages, decision-level
Full analysis by section
Every exhibit cited to a live source
Source annex — all PMIDs and live URLs

XLS

Excel Workbook

Access Scenario Model

A live, editable model mapping coverage posture and PA architecture to addressable access, with labelled, sourced assumptions your analyst can adjust.

Coverage posture by payer archetype
PA-impact adjustment on the addressable pool
Access-timing scenarios
Evidence-gap risk weighting
Sensitivity on coverage-decision timing

PPT

PowerPoint · Optional Add-on

Executive Deck

Five slides your leadership team can act on — structured around decisions, not descriptions.

Market opportunity — cohort-level
Competitive position and key threats
Payer readiness gap
Patient capture scenarios
Priority decisions and open questions

Sample Output

Exhibit 5 — US coverage architecture, NSCLC IO agents.

Illustrative coverage map. Postures are precedent-typical and shown to demonstrate the structure and sourcing standard — on a commissioned brief every coverage claim is cited to a live policy document at the exhibit foot.

Coverage Architecture — NSCLC IO Agents · US · Q2 2026 Sample · Illustrative

Agent	Coverage posture	Biomarker requirement	Step / line restriction	Evidence basis
PembrolizumabKeytruda · Merck	Broad	PD-L1 IHC (setting-dependent)	1L per label; limited step	KEYNOTE precedent
Nivolumab + ipilimumabOpdivo + Yervoy · BMS	Broad	Generally none for combo	1L doublet; PA documentation	CheckMate precedent
AtezolizumabTecentriq · Roche	Restricted	PD-L1 (assay-specific)	Step edits in some plans	IMpower precedent
[YOUR ASSET][Client] · Confidential	Pre-approval	Per proposed label	Modelled at intake	Your trial vs. precedent

Sources: Coverage postures are precedent-typical and illustrative for this sample page. On a commissioned brief, each coverage claim is cited to a live payer policy, FDA label, or HTA document and verified at point of writing.

Source Standard

Every figure is live-sourced before delivery. If a number cannot be verified, it does not appear.

This is a field where AI confidently reproduces outdated epidemiology, superseded payer policy, and retracted analyses. AXLRx uses none of its own memory as a source. Every figure your team receives is verified against a live document at the time of writing.

A wrong number in front of your payer or your leadership team is not recoverable in the same meeting.

Every claim cited to a live PMID, ClinicalTrials.gov ID, or URL at point of writing — uncited claims are dropped, not estimated
PubMed metadata fetched live during authoring — model memory produces incorrect author and journal data even on correct PMIDs
Numeric cross-check: the specific figure must appear in the cited source, not merely be consistent with its topic
Independent audit pass after generation — broken links, unsourced claims, and numeric inconsistencies flagged before delivery
Drop gate: any figure that cannot clear the above is removed. No confidence tiers. No exceptions.

Questions

What commercial teams ask before commissioning.

Scope

Is this national or plan-specific?

We map coverage by payer archetype and call out the major regional and PBM variation. Plan-specific deep dives are available as a scoped add-on.

Sourcing

Are coverage claims from current policy?

Every coverage and PA claim is cited to a live policy document at the point of writing — model memory routinely reproduces superseded policy, so none is used.

Delivery

How fast?

72 hours from scope confirmation, with a 30-minute readout call. A 48-hour track is available for deadlines.

Format

What do we receive?

A PDF access brief, an editable access-scenario Excel model, and an optional executive deck for leadership alignment.

Process

Can you focus on just the evidence-gap analysis?

Yes. Scoped standalone sections — including the gap analysis vs. your trial design — are available and priced by scope.

Commission Your Analysis

Tell us your asset. Your team has the intelligence in 72 hours.

We build from your asset's clinical profile — mechanism, biomarker strategy, proposed label, and target cohort. Scope confirmation takes one call.

Start Your Request

Or see a sample output to review the depth before committing.

Submit your asset profile

Drug, mechanism, proposed indication, target cohort, geography. Five minutes via the intake form.

Scope confirmed in 24 hours

We confirm scope with your team, clarify ambiguities, and lock delivery timing.

Your access analysis, delivered in 72 hours

PDF intelligence document, Excel model, and optional executive deck — with a 30-minute readout call included.